Gastrointestinal disorders include conditions such as peptic Ulcer, inflammatory bowel diseases IBD (Crohn’s disease & Ulcerative Colitis), irritable bowel syndrome (IBS) & Constipation.
 
Longer term, market growth exists for IBD and IBS given the continued progression in clinical development of novel drug mechanisms.  These remain as under-diagnosed and underserved conditions that impact very large populations of patients across a wide demographic within developed markets.  
 
Strong commercial opportunity exist in areas such as Chronic Constipation (CC), Opioid Induced Constipation (OIC), Constipation Predominant Irritable Bowel Syndrome (IBS-C) and diarrhea predominant IBS-D.